Ainos, Inc. (AIMD)
NASDAQ: AIMD · Real-Time Price · USD
0.430
+0.004 (0.94%)
Nov 20, 2024, 4:00 PM EST - Market closed
Ainos Revenue
Ainos had revenue of $40.63K in the twelve months ending September 30, 2024, down -96.44% year-over-year. In the year 2023, Ainos had annual revenue of $122.11K, down -96.53%.
Revenue (ttm)
$40.63K
Revenue Growth
-96.44%
P/S Ratio
73.87
Revenue / Employee
$883
Employees
46
Market Cap
5.95M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 122.11K | -3.40M | -96.53% |
| Dec 31, 2022 | 3.52M | 2.93M | 491.97% |
| Dec 31, 2021 | 594.56K | 578.00K | 3,489.71% |
| Dec 31, 2020 | 16.56K | 4.83K | 41.19% |
| Dec 31, 2019 | 11.73K | -65.99K | -84.91% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cutera | 155.21M |
| SunLink Health Systems | 31.81M |
| Intelligent Bio Solutions | 3.19M |
| Biora Therapeutics | 892.00K |
| Mangoceuticals | 755.00K |
AIMD News
- 7 days ago - Water Tower Research Highlights IRB Approval for the Ainos VELDONA Clinical Sjogren's Trial Alongside 3Q24 Earnings and Developments - Accesswire
- 9 days ago - Ainos Announces IRB Approval for Sjögren's Syndrome Clinical Study at Shuang Ho Hospital, Affiliated with Taipei Medical University, and Plans to Initiate New Phase of Treatment Evaluation in Q1 2025 - Accesswire
- 12 days ago - Ainos Takes Decisive Action to Protect Stockholder Interests and Combat Potential Illegal Trading Activities - Accesswire
- 14 days ago - Ainos Reports Third Quarter 2024 Financial Results - Accesswire
- 23 days ago - Ainos Expands Patent Portfolio With Strategic Shareholder's Cutting-Edge Technology Assets - Accesswire
- 27 days ago - Ainos Highlights VELDONA Clinical Advancements and Market Potential in Water Tower Research Spotlight Podcast - Accesswire
- 6 weeks ago - Ainos Advances Healthcare and Industrial Innovations with AI Nose and VELDONA Technologies - Accesswire
- 2 months ago - Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONA - Accesswire